Search results
In RA Treatment, Don't Overlook Underlying CV Risks
Medscape· 6 days agoRheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic...
Needham & Company LLC Increases Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 5 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) had its target price lifted by equities researchers at Needham & Company LLC from $16.00 to $18.00 in a note issued to investors on Wednesday ...
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 7 days agoQ: How do you expect the atopic dermatitis market to evolve, especially with physicians' growing comfort with Opzelura...Chief Financial Officer, stated that gross-to-net is expected to stabilize ...
Tuesday's Health Report: What your feet can say about your health
WBRZ 2 Baton Rouge· 5 days agoYour feet can actually tell you about your well being. Say a patient presents with swelling of the skin or the feet, sometimes it's related to heart disease or kidney disease or lymphedema or vascular disease.
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $18.00
ETF DAILY NEWS· 4 days agoArcutis Biotherapeutics (NASDAQ:ARQT – Free Report) had its price target lifted by Mizuho from $17.00 to $18.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating ...
CDSCO approves antibody for rare skin disorder in Indian adults
Investing.com· 7 days agoCDSCO approves antibody for rare skin disorder in Indian adults
How skin conditions like vitiligo affect mental health
WFLA· 5 days agoTAMPA (BLOOM) – May is Mental Health Month, a time to raise awareness about the critical connection...
Urine Tests Could Be 'Enormous Step' in Diagnosing Cancer
Medscape· 15 hours agoThe next frontier in cancer detection could be the humble urine test. Emerging science suggests that...
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease...
Tri-County Times· 4 days ago- AbbVie will present 15 abstracts, including three oral presentations, in Crohn's disease and ulcerative colitis reinforcing AbbVie's commitment to advancing the standards of care in inflammatory bowel diseases (IBD)
AbbVie Inc. (NYSE:ABBV) to Post Q2 2024 Earnings of $3.01 Per Share, Zacks Research Forecasts
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Free Report) – Analysts at Zacks Research lifted their Q2 2024 earnings estimates for shares of AbbVie in a research report issued to clients and investors on Tuesday ...